MA44008A - 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b - Google Patents
1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2bInfo
- Publication number
- MA44008A MA44008A MA044008A MA44008A MA44008A MA 44008 A MA44008 A MA 44008A MA 044008 A MA044008 A MA 044008A MA 44008 A MA44008 A MA 44008A MA 44008 A MA44008 A MA 44008A
- Authority
- MA
- Morocco
- Prior art keywords
- nr2b
- substituted
- selective nmda
- nmda modulators
- triazoles used
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662293680P | 2016-02-10 | 2016-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44008A true MA44008A (fr) | 2018-12-19 |
Family
ID=58054551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044008A MA44008A (fr) | 2016-02-10 | 2017-02-09 | 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10071988B2 (fr) |
| EP (1) | EP3414233A1 (fr) |
| JP (1) | JP6923543B2 (fr) |
| KR (1) | KR20180108822A (fr) |
| CN (1) | CN109071488B (fr) |
| AU (1) | AU2017217542B2 (fr) |
| BR (1) | BR112018016329A2 (fr) |
| CA (1) | CA3014314A1 (fr) |
| EA (1) | EA201891799A1 (fr) |
| IL (1) | IL261046B (fr) |
| MA (1) | MA44008A (fr) |
| MX (1) | MX2018009752A (fr) |
| SG (1) | SG11201806750WA (fr) |
| WO (1) | WO2017139428A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3180329T3 (pl) | 2014-08-15 | 2020-08-24 | Janssen Pharmaceuticals, Inc. | Triazole jako inhibitory receptora NR2B |
| WO2016025918A1 (fr) | 2014-08-15 | 2016-02-18 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
| MD3319963T2 (ro) | 2015-07-09 | 2020-05-31 | Janssen Pharmaceutica Nv | 4-Azaindoli substituiți și utilizarea lor în calitate de modulatori ai receptorului GluN2B |
| WO2017139428A1 (fr) | 2016-02-10 | 2017-08-17 | Janssen Pharmaceutica Nv | 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| MA52244A (fr) | 2018-04-04 | 2021-02-17 | Janssen Pharmaceutica Nv | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
| CA3103351A1 (fr) * | 2018-07-03 | 2020-01-09 | Helmholtz-Zentrum Fur Infektionsforschung Gmbh | Agonistes inverses de pqsr |
| WO2020249802A1 (fr) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyrazolo-pyrazines substituées et leur utilisation en tant que modulateurs du récepteur de glun2b |
| US11459336B2 (en) | 2019-06-14 | 2022-10-04 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
| EP3982958A1 (fr) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
| KR20220024511A (ko) | 2019-06-14 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | 치환된 피라졸로-피리딘 아미드 및 GluN2B 수용체 조절제로서의 이의 용도 |
| US20220324860A1 (en) | 2019-06-14 | 2022-10-13 | Janssen Pharmaceutica Nv | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| JP2022538774A (ja) | 2019-06-14 | 2022-09-06 | ヤンセン ファーマシューティカ エヌ．ベー． | ピリジンカルバメート及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 |
| CN110128354A (zh) * | 2019-06-20 | 2019-08-16 | 大连大学 | 一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法 |
| WO2024077292A2 (fr) * | 2022-10-07 | 2024-04-11 | Augusta University Research Institute, Inc. | Synthèse de conjugués d'ains utilisés en tant qu'agents anti-inflammatoires et analgésiques à l'aide de l'approche d'hybridation moléculaire |
| CN115947692A (zh) * | 2022-12-28 | 2023-04-11 | 上海再启生物技术有限公司 | 一种制备2-氯-4-(甲氧基甲基)嘧啶的方法 |
| WO2024208292A1 (fr) * | 2023-04-04 | 2024-10-10 | 江苏亚虹医药科技股份有限公司 | Inhibiteur de protéase 1 spécifique de l'ubiquitine, son procédé de préparation et son utilisation médicale |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| US7534800B2 (en) | 2002-03-28 | 2009-05-19 | Eisai R & D Development Co., Ltd. | 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| EA200601266A1 (ru) * | 2004-02-18 | 2007-02-27 | Астразенека Аб | Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата |
| US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| CA2686651C (fr) | 2007-05-25 | 2015-11-24 | Abbott Gmbh & Co. Kg | Composes heterocycliques comme modulateurs positifs du recepteur metabotropique du glutamate 2 (recepteur mglu2) |
| CN101842357A (zh) | 2007-08-30 | 2010-09-22 | 武田药品工业株式会社 | 取代的吡唑衍生物 |
| US20100249164A1 (en) | 2007-10-31 | 2010-09-30 | Renger John J | Modulation of sleep with nr2b receptor antagonists |
| RU2499598C2 (ru) * | 2008-03-27 | 2013-11-27 | Евотек Интернациональ Гмбх | Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов |
| MX2011001019A (es) | 2008-08-05 | 2011-03-25 | Daiichi Sankyo Co Ltd | Derivados de imidazopiridin-2-ona. |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| RU2517181C2 (ru) | 2008-10-16 | 2014-05-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов |
| AU2009324894B2 (en) | 2008-11-25 | 2015-04-09 | University Of Rochester | MLK inhibitors and methods of use |
| US8969342B2 (en) | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| US8765784B2 (en) | 2010-06-09 | 2014-07-01 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of MGLUR2 |
| JP2012188363A (ja) | 2011-03-09 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | アザベンゾイミダゾロン誘導体 |
| WO2013130855A1 (fr) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Dérivés d'indazole |
| WO2014124651A1 (fr) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Dérivés de pyrrolidine-2-acide carboxylique utilisés en tant qu'antagonistes de iglur |
| JP2016516710A (ja) | 2013-03-13 | 2016-06-09 | アッヴィ・インコーポレイテッド | ピリジン系ｃｄｋ９キナーゼ阻害薬 |
| WO2016025918A1 (fr) | 2014-08-15 | 2016-02-18 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
| PL3180329T3 (pl) | 2014-08-15 | 2020-08-24 | Janssen Pharmaceuticals, Inc. | Triazole jako inhibitory receptora NR2B |
| MD3319963T2 (ro) | 2015-07-09 | 2020-05-31 | Janssen Pharmaceutica Nv | 4-Azaindoli substituiți și utilizarea lor în calitate de modulatori ai receptorului GluN2B |
| WO2017139428A1 (fr) | 2016-02-10 | 2017-08-17 | Janssen Pharmaceutica Nv | 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| MA52244A (fr) | 2018-04-04 | 2021-02-17 | Janssen Pharmaceutica Nv | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
-
2017
- 2017-02-09 WO PCT/US2017/017093 patent/WO2017139428A1/fr active Application Filing
- 2017-02-09 SG SG11201806750WA patent/SG11201806750WA/en unknown
- 2017-02-09 EP EP17705768.4A patent/EP3414233A1/fr not_active Withdrawn
- 2017-02-09 EA EA201891799A patent/EA201891799A1/ru unknown
- 2017-02-09 CN CN201780022887.6A patent/CN109071488B/zh active Active
- 2017-02-09 CA CA3014314A patent/CA3014314A1/fr active Pending
- 2017-02-09 AU AU2017217542A patent/AU2017217542B2/en active Active
- 2017-02-09 MX MX2018009752A patent/MX2018009752A/es unknown
- 2017-02-09 KR KR1020187026142A patent/KR20180108822A/ko active Search and Examination
- 2017-02-09 US US15/428,710 patent/US10071988B2/en active Active
- 2017-02-09 JP JP2018541636A patent/JP6923543B2/ja active Active
- 2017-02-09 BR BR112018016329A patent/BR112018016329A2/pt not_active Application Discontinuation
- 2017-02-09 MA MA044008A patent/MA44008A/fr unknown
-
2018
- 2018-07-26 US US16/046,332 patent/US10233173B2/en active Active
- 2018-08-08 IL IL261046A patent/IL261046B/en unknown
- 2018-12-31 US US16/237,333 patent/US10766880B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6923543B2 (ja) | 2021-08-18 |
| JP2019504854A (ja) | 2019-02-21 |
| US20190135791A1 (en) | 2019-05-09 |
| EA201891799A1 (ru) | 2019-02-28 |
| SG11201806750WA (en) | 2018-09-27 |
| US10766880B2 (en) | 2020-09-08 |
| AU2017217542B2 (en) | 2021-06-03 |
| WO2017139428A1 (fr) | 2017-08-17 |
| IL261046A (en) | 2019-02-28 |
| US10071988B2 (en) | 2018-09-11 |
| US10233173B2 (en) | 2019-03-19 |
| MX2018009752A (es) | 2019-02-07 |
| KR20180108822A (ko) | 2018-10-04 |
| AU2017217542A1 (en) | 2018-08-23 |
| US20180334451A1 (en) | 2018-11-22 |
| BR112018016329A2 (pt) | 2018-12-18 |
| EP3414233A1 (fr) | 2018-12-19 |
| IL261046B (en) | 2021-09-30 |
| US20170226089A1 (en) | 2017-08-10 |
| CA3014314A1 (fr) | 2017-08-17 |
| CN109071488B (zh) | 2021-08-13 |
| CN109071488A (zh) | 2018-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44008A (fr) | 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b | |
| FR24C1009I1 (fr) | Composés utilisés comme inhibiteurs de kinase | |
| CY1123853T1 (el) | Ρυθμιστες nrf2 | |
| MA52157A (fr) | Dinucléotides cycliques de purine utilisés comme modulateurs de sting | |
| EP3478249A4 (fr) | Compositions de microcapsules stables | |
| EA201891209A1 (ru) | Модуляторы хемокиновых рецепторов | |
| MX2022000053A (es) | Moduladores de interaccion de sestrina-gator2 y sus usos. | |
| EP3408268B8 (fr) | Derives de benzimidazole comme des modulateurs de ror-gamma | |
| MA47013A (fr) | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase | |
| MA46373A (fr) | Composés utilisés comme modulateurs de ror gamma | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
| EP3302437B8 (fr) | Formulations de cannabinoïdes stables | |
| DK3294713T3 (da) | Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer | |
| WO2015191951A3 (fr) | Modulation d'activité du complément | |
| DK3331863T3 (da) | Hidtil ukendte forbindelser som ror-gamma-modulatorer | |
| EP3462885A4 (fr) | Formulations de cannabinoïdes stables | |
| WO2015120138A3 (fr) | Agents modulant la signalisation rgmb-neogénine-bmp et leurs procédés d'utilisation | |
| EA201790570A1 (ru) | Модуляторы р2х7 | |
| MX2017008390A (es) | Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato. | |
| EP3346970A4 (fr) | Composition pour modifier la couleur de fibres de kératine | |
| EA201791500A1 (ru) | Циклопропанкарбоксамидные модуляторы муковисцидозного трансмембранного регулятора проводимости | |
| DK3571394T3 (da) | Inertireaktion for netstabilitet | |
| AU2016361427A8 (en) | Platinum anticancer agents | |
| EA201792262A1 (ru) | Пироглутамат вортиоксетина |